Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: corticotropin Clear all
Completed Phase 4 Interventional Results available

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

NCT02919761
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
San Leandro, California • Upland, California • Boynton Beach, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 23, 2026, 5:03 PM EDT
Terminated Phase 4 Interventional Results available

Use of CXCL9 as a Biomarker of Acthar Efficacy

NCT02523092
View directory record Official record
Conditions
Sarcoidosis
Interventions
Acthar gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 23, 2026, 5:03 PM EDT
Not listed No phase listed Observational

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

NCT03644771
View directory record Official record
Conditions
Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function
Interventions
Acthar
Drug
Lead sponsor
Greater Boston Medical Associates
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 23, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma

NCT06344143
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS)
Interventions
Various labs and imaging tests
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 4 Interventional

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

NCT03419650
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
ACTHar
Drug
Lead sponsor
IRIS Research and Development, LLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Sep 23, 2026, 5:03 PM EDT
Not listed Phase 4 Interventional

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

NCT05546047
View directory record Official record
Conditions
Fibrillary Glomerulonephritis
Interventions
Acthar Gel 80 UNT/ML Injectable Solution
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Lawrenceville, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock

NCT00005890
View directory record Official record
Conditions
Septic Shock
Interventions
corticotropin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
1 Month to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

NCT00422201
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Mifepristone
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Results available

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

NCT02633046
View directory record Official record
Conditions
Idiopathic Focal Segmental Glomerulosclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
21
States / cities
Birmingham, Alabama • Tucson, Arizona • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 23, 2026, 5:03 PM EDT
Not listed Not applicable Interventional

Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses

NCT01900093
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Aaron Miller
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 23, 2026, 5:03 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

NCT00854750
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR
Drug
Lead sponsor
Elliot Frohman
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 23, 2026, 5:03 PM EDT
Not listed No phase listed Observational

Registry for Advanced Sarcodiosis

NCT03769987
View directory record Official record
Conditions
Sarcoidosis
Interventions
observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 23, 2026, 5:03 PM EDT
Withdrawn Not applicable Interventional

ACTH Treatment of APOL1- Associated Nephropathy

NCT02006849
View directory record Official record
Conditions
Kidney Disease
Interventions
Acthar
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00569582
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Sep 23, 2026, 5:03 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

NCT03905603
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
ACTH, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
20 Years to 49 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 23, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

NCT02749227
View directory record Official record
Conditions
Pituitary Tumor, ACTH-producing Pituitary Tumour
Interventions
Pasireotide LAR
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 23, 2026, 5:03 PM EDT
Not listed Phase 2Phase 3 Interventional

ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial

NCT02348905
View directory record Official record
Conditions
Sarcoidosis, Cutaneous Sarcoidosis
Interventions
ACTHAR Gel 40 units twice weekly, ACTHAR Gel 80 units twice weekly.
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)

NCT02931175
View directory record Official record
Conditions
Uveitis
Interventions
ACTH gel
Drug
Lead sponsor
Quan Dong Nguyen
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Waltham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 23, 2026, 5:03 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation

NCT01421797
View directory record Official record
Conditions
Hyperandrogenemia, Polycystic Ovary Syndrome, Obesity
Interventions
Dexamethasone, Cortrosyn
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

NCT04308590
View directory record Official record
Conditions
Hypercortisolism
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Stanford, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 23, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT05696613
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
SNP-ACTH (1-39) Gel, Rituximab
Drug
Lead sponsor
Cerium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Los Angeles, California • San Dimas, California • Tarzana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Results available

Treatment of CNS Sarcoidosis With H.P. Acthar Gel

NCT02298491
View directory record Official record
Conditions
CNS Sarcoidosis
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 23, 2026, 5:03 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

NCT04037605
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

NCT00989781
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
3-D Ultrasound, recombinant human chorionic gonadotropin, Recombinant human follicle stimulating hormone, Adrenocorticotropin, Dexamethasone, Glucose
Radiation · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 23, 2026, 5:03 PM EDT